These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27481878)

  • 1. Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.
    Peyrin-Biroulet L; Lönnfors S; Roblin X; Danese S; Avedano L
    J Crohns Colitis; 2017 Jan; 11(1):128-133. PubMed ID: 27481878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.
    Peyrin-Biroulet L; Lönnfors S; Avedano L; Danese S
    United European Gastroenterol J; 2019 Dec; 7(10):1345-1352. PubMed ID: 31839960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2016 Nov; 10(11):1362-1365. PubMed ID: 27112706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease.
    Macaluso FS; Leone S; Previtali E; Ventimiglia M; Armuzzi A; Orlando A;
    Dig Liver Dis; 2020 Nov; 52(11):1304-1309. PubMed ID: 32807691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
    Teixeira FV; Kotze PG; Damião AO; Miszputen SJ
    Arq Gastroenterol; 2015; 52(1):76-80. PubMed ID: 26017088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians.
    Park SK; Moon W; Kim ES; Park SH; Park DI
    Korean J Gastroenterol; 2019 Dec; 74(6):333-340. PubMed ID: 31870139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.
    Sullivan E; Piercy J; Waller J; Black CM; Kachroo S
    PLoS One; 2017; 12(4):e0175826. PubMed ID: 28410403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2014 Nov; 8(11):1548-50. PubMed ID: 25008477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of biosimilars in paediatric inflammatory bowel disease.
    Jongsma MME; Vulto A; de Ridder L
    Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients.
    Garcia KS; Facas BP; Machado MB; Teixeira FV; Avedano L; Lönnfors S; Hossne RS; Peyrin-Biroulet L; Queiroz NSF
    Therap Adv Gastroenterol; 2021; 14():17562848211013249. PubMed ID: 34046083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
    McConachie S; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in Crohn's Disease and Ulcerative Colitis.
    Wolf DC
    Inflamm Bowel Dis; 2016 Apr; 22(4):994-7. PubMed ID: 26933749
    [No Abstract]   [Full Text] [Related]  

  • 13. Biosimilars in paediatric inflammatory bowel disease.
    Sieczkowska-Golub J; Jarzebicka D; Oracz G; Kierkus J
    World J Gastroenterol; 2018 Sep; 24(35):4021-4027. PubMed ID: 30254406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
    Gils A; Van Stappen T; Dreesen E; Storme R; Vermeire S; Declerck PJ
    Inflamm Bowel Dis; 2016 Apr; 22(4):969-75. PubMed ID: 26954707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
    Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
    Jahnsen J; Detlie TE; Vatn S; Ricanek P
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
    Annese V; Vecchi M;
    Dig Liver Dis; 2014 Nov; 46(11):963-8. PubMed ID: 25139379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists.
    Baji P; Gulácsi L; Golovics PA; Lovász BD; Péntek M; Brodszky V; Rencz F; Lakatos PL
    Value Health Reg Issues; 2016 Sep; 10():85-90. PubMed ID: 27881284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey.
    Frantzen L; Cohen JD; Tropé S; Beck M; Munos A; Sittler MA; Diebolt R; Metzler I; Sordet C
    Joint Bone Spine; 2019 Jul; 86(4):491-496. PubMed ID: 30659920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.